



DEMENTIA DETECTION APPLICATIONS & DIAGNOSTIC SOLUTIONS



DEMENTIA DETECTION APPLICATIONS & DIAGNOSTIC SOLUTIONS

EXPERTS IN NEURODEGENERATIVE DISEASE RESEARCH

GT Diagnostics develops readily deployable e-platform tools that range from interactive well-being apps that can be used at home to comprehensive tools for expert use targeting the diagnosis and monitoring of dementia.

GT Diagnostics' tools are designed to be made available through various service providers including personal advice and support systems, residential and non-residential care, and specialised dementia centres.

About Us

Genting TauRx Diagnostic Centre Sdn Bhd and its wholly owned subsidiary GT Diagnostics (UK) Limited (jointly GT Diagnostics) was formed to enable basic research in dementia diagnosis to transition into clinical development.

GT Diagnostics is currently in the final development stage of four diagnostic and monitoring tools for dementia.

Vision & Mission

Driven by the values of our founding partners, we aim to change the diagnostic landscape and market in dementia. Our mission is to provide the missing tools for early diagnosis and monitoring of disease progression in dementia; tools that can be used in the comfort of one's home to tools that require administration by experts. These tools are designed with the aim to benefit millions who are worried about their cognitive health.

A Complete Partnership

Genting Berhad are embracing innovation and the adoption of new technology while TauRx Therapeutics are committed to the development of a treatment for dementia. As a result of their partnership, they have founded GT Diagnostics to develop intelligent tools to assist with early dementia detection.



www.gtdiag.com

contact@gtdiag.com | +44 (0)1224 440990 395 King Street, Aberdeen, AB24 5RP, UK

🚯 🖸 🛅 gtdiagnostics







A TEAM WITH MORE THAN A CENTURY OF COMBINED EXPERIENCE

GT Diagnostics develops readily deployable e-platform tools that range from interactive well-being apps that can be used at home to comprehensive tools for expert use targeting the diagnosis and monitoring of dementia.

GT Diagnostics' tools are designed to be made available through various service providers including personal advice and support systems, residential and non-residential care, and specialised dementia

Team Leads



PROF BJOERN SCHELTER

- Over 100 scientific publications
- Almost 5000 citations

For more than 20 years, Professor Bjoern Schelter has led a scientific research team dedicated to finding novel data analysis techniques. For 7 years, he has focused on the development of novel diagnostic tools for the diagnosis of dementias.

LINDA SOMMERLADE

Head of Operations

With more than 15 years of experience in data analysis, QMS and project management in the Life Sciences, Dr Sommerlade leads the development of HiPAL, HiPAL Pro and SigNeXx.

KASIA LECH

QMS Lead

Kasia Lech with her outstanding attention to detail leads our QMS activities. This is done with a clear focus on meeting regulatory submission timelines. External validation of our efforts is provided by various consultants.

HELEN SHIELLS

Lead for PsyCoXx (Maternity leave)

Dr Shiells looks back to more than 8 years experience in data-based modelling and statistics in dementia research. She spearheads the development of PsyCoXx.

MILES WELSTEAD

Psychologist/Lead for PsyCoXx (Maternity cover)

Miles Welstead has been involved in the development of Hipal, Hipal Pro, and PsyCoXx, specifically working to ensure that cognitive assessment elements of these tests are accurate and informative.

Get in touch



Bringing Dementia Diagnostics into the 21st Century.

Genting TauRx Diagnostic Centre Sdn Bhd, a company established in Malaysia, and its wholly owned subsidiary GT Diagnostics (UK) Limited, was founded as a collaboration between Genting Berhad and TauRx Pharmaceuticals Ltd Group, with the vision to change the diagnostic landscape and market in dementia.



Global Context

ONE OF THE WORLD'S GREATEST UNMET MEDICAL NEEDS

EPIDEMIC

As the world's population ages, the prevalence of Alzheimer's Disease is predicted to reach epidemic proportions.

IMPACT

Huge financial impact on public healthcare and devastating for patients, families and caregivers.

132 MILLION

50m people currently living with Alzheimer's Disease predicted to rise to 75m by 2030 and 132m by 2050.

\$1 TRILLION

Health care payments for people with Alzheimer's Disease forecast to increase from \$290bn in 2019 to \$1.1tr in 2050.

New Patient Journey

Initial appointment, waiting room: advanced diagnostic tools confirm.

2

OUR PRODUCTS

First steps taken at home using engaging and interactive assessment tools. Wemory Testing

HIPALPRO Advanced Memory Testing

Cognitive Testing



Treatment prescribed, effect measured by accessible, ongoing monitoring tools.

> annumation

3

Current Patient Journey




Initial suspicion of cognitive impairment/AD.

THE EXTENT OF THE PROBLEM...

3 people in 500^{*} are currently diagnosed with dementia.

9 people in 500^{*} have dementia but are undiagnosed.

90 people in 500^{*} have changes in their brain that could lead to dementia.





Wait period...



Specialist appointment, tests...



Diagnosis of AD.



Cognitive assessment through expensive and non-mobile technologies. Specialist advice on possible (symptomatic) treatment.



Management of symptoms.



Outcome...





DEMENTIA DETECTION APPLICATIONS & DIAGNOSTIC SOLUTIONS

GT Diagnostics develops readily deployable e-platform tools that range from interactive well-being apps that can be used at home to comprehensive tools for expert use targeting the diagnosis and monitoring of dementia. GT Diagnostics' tools are designed to be made available through various service providers including personal advice and support systems, residential and non-residential care, and specialised dementia centres.



An engaging and interactive well-being app that permits those concerned about their cognitive health to monitor their status at home.



A self-administered engaging and interactive tool running on a tablet, supporting clinicians in evaluating objective and subjective memory and mental processing speed.



A specialised neuropsychological testing tool for clinicians to use in their assessment of patients with suspected or confirmed dementia, including Alzheimer's disease.



A non-invasive, advanced EEG-based analysis tool, using standard EEG acquisition devices to provide an objective measure of brain connectivity.





A well-being app that permits those worried about their cognitive health to monitor their status at home.

Memory Testing

Start Assessment


II Statistics

TE Settinge

A Home

Imagine you could regularly test your cognitive performance in the comfort of your home. Imagine subtle changes could be identified very early. Imagine the data collected over the years is not wasted but could be shared readily with experts who can not only help you but also have access to more advanced tools.








A self-administered engaging and interactive tool running on a tablet, HiPAL Pro supports clinicians with professionally evaluating objective and subjective memory and mental processing speed, and can be used in waiting rooms of primary care facilities or expert centres.

HiPAL Pro is GT Diagnostics' professional tool which is currently under development with the aim to be able to seamlessly integrate with HiPAL.

Through more comprehensive testing, HiPAL Pro is designed to provide an advanced output aimed at assisting in the diagnosis and monitoring of dementia, in particular, Alzheimer's disease.

With minimal set-up by the clinician, the application presents a self-administered psychometric test to the patient, examining aspects of cognition such as memory and executive function.

Individual patient results are presented as predicted scores for well-established standard questionnaire based assessments, allowing the clinician to evaluate their patient according to well-defined and characterised measures.



											6 0
		GIDMONOSTICS	HIPAL PRO						Aller som	Clarck 🛫	
hu 26 Aug		*0						1 (1000) (10)	(in the part of the second	7	
			Surgers ID	Site - 1	5es - 17	Apr - 2	Last Assessment date	Predicted MMSE 1	Predicted ADASCeg T	Actions	
Relate the numbers in the middle with the symbols below according to the top picture		Ð	50100	Preeman Hospital	Mater	65	23 put 2021	24	16.67	-	
			solor	Royal Berkshire NirtS	Male	45	16 Dec 2021	20	36.33	-	
			50102	Royal Marsden Hospital	Female	-	01 Oct 2021	31	26.33	-	
~	-	-	50103	Royal Marsden Höspital	Male	71	29 Apr 2021	22	26.67	-	
TST	- [θ	50104	Noyal Berksmite RMS	Mare	50	21 Jun 2021	25	12.67	ter.	
1 2 3	4	5	50105	Royal Derkshire NHS	Particle	-	19 Apr 2021	23	16	-	
		-	50106	Barning Mospital	Male	64	17 Mar 2021	20	24		
		-	36107	Banting Hospital	Male	78	26 Apr 2021	25	18.67		
	-	+	50108	Ratu Gajah Hospital	Male	82	02 Nov 2021	24	8.67	-	
			50109	Freeman Hospital	Female	77	14 Jul 2021	25	36	-	
6 7	8	9	50110	Batu Gajah Hospital	Male	71	27 Jun 2021	30	8	-	
			50111	Barring Hospital	Male	-67	11 Oct 2021	24	*		
	- 1		50112	Banu Gajah Hospital	Male	90	06 Apr 2021	71	7	10	
T 1 4	6. 18.	12 3	ng 28 from 48 Geo						** ** **		
	+	0 ^									




- Engaging and interactive testing
- Professional tool
- Short tests supporting diagnosis
- Improves efficiency
- Accurate cognitive health results
- Integrates with other tools
- Enables monitoring over time




A specialised neuropsychological testing tool for clinicians to use in their assessment of patients with suspected or confirmed dementia, including Alzheimer's disease.

PsyCoXx can be used flexibly to aid in diagnosis and to assess or monitor patients across multiple disease domains using a novel, proprietary algorithm.

PsyCoXx is administered using a computer and presents the clinician with questions tailored to individual patient ability. The test calculates patient scores and measures confidence in these scores, across the three different domains. The patient scores and confidence intervals are dynamically updated as the patient answers more questions, until a confidence threshold is met. Clinicians then have patient scores across the three disease-relevant domains, which can be used to aid in diagnosis or to monitor disease severity.





PROFESSIONAL TOOL | PROVIDES FULL 3D VIEW OF A PATIENT | COMPUTER ADAPTIVE



www.gtdiag.com

contact@gtdiag.com | +44 (0)1224 440990 395 King Street, Aberdeen, AB24 5RP, UK

() In gtdiagnostics